What is MIDI?
MIDI, Inc. stands as a prominent veteran-owned biotechnology enterprise, distinguished by its expertise in complex chromatographic data analysis and advanced pattern recognition. At the core of its technological portfolio is the Sherlock software, a globally recognized platform essential for the precise identification of microbial communities, bacteria, and intricate matrices such as fire debris and edible oils. The company serves as a vital partner to research institutions and public health laboratories, offering both proprietary microbial identification systems and comprehensive contract laboratory services. Through its commitment to rapid, cost-effective analytical solutions, MIDI has established itself as a cornerstone in the field of diagnostic biotechnology and environmental forensics.
How much funding has MIDI raised?
MIDI has raised a total of $297K across 2 funding rounds:
Debt
$150K
Debt
$147K
Debt (2020): $150K with participation from PPP
Debt (2021): $147K led by PPP
Key Investors in MIDI
PPP
Public-Private Partnership
What's next for MIDI?
With the successful closure of this late-stage financing, MIDI is well-positioned to accelerate its strategic growth initiatives. The company is expected to focus on scaling its Sherlock software capabilities and expanding its footprint within the global research and public health sectors. By prioritizing the enhancement of its contract laboratory services, MIDI aims to address the increasing demand for high-fidelity microbial identification. This capital injection provides the necessary runway to refine its pattern recognition algorithms and potentially explore new market verticals, ensuring that the firm remains at the forefront of chromatographic innovation and diagnostic excellence.
See full MIDI company page
